Brief: Inozyme Pharma Announces Dosing Of First Infant With Enpp1 Deficiency In A Phase 1B Trial Of Inz-701

Inozyme Pharma

27/06/2023 14:02

June 27 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME PHARMA ANNOUNCES DOSING OF FIRST INFANT WITH ENPP1
DEFICIENCY IN A PHASE 1B TRIAL OF INZ-701
    * INOZYME PHARMA ANNOUNCES DOSING OF FIRST INFANT WITH ENPP1
DEFICIENCY IN A PHASE 1B TRIAL OF INZ-701
    * INOZYME PHARMA INC - PIVOTAL TRIAL OF INZ-701 IN PEDIATRIC
PATIENTS WHICH IS PLANNED TO BEGIN IN Q3 2023

Source text for Eikon:  ID:nGNX34RKYL 
Further company coverage:  INZY.O 

 ((Reuters.Briefs@thomsonreuters.com;))